Table 1 The baseline characteristics of the serum survivin-2B measurements using ELISA in RA patients.

From: The proto-oncogene survivin splice variant 2B is induced by PDGF and leads to cell proliferation in rheumatoid arthritis fibroblast-like synoviocytes

 

Survivin-2B high (≥ 12 ng/ml)

Survivin-2B low (<12 ng/ml)

p-value

 

(n = 18)

(n = 21)

 

Age

68.9 ± 14.3

66.6 ± 9.7

0.553*

Sex (Female/Male)

F 17/M 1

F 19/M 2

0.643†

Duration of RA (year)

10.8 ± 9.2

12.6 ± 9.9

0.560*

Dose of glucocorticoids (prednisolone, mg/day)

3.2 ± 2.1

3.2 ± 2.9

0.973*

Current use of non-biologic DMARDs

15 (83.3%)

20 (95.2%)

0.246†,‡

Current use of biologics

7 (38.9%)

7 (33.3%)

0.718†,§

Disease activity score of RA (DAS28-ESR)

4.64 ± 1.10

3.64 ± 1.67

0.037**

  1. Mean ± Standard Deviation (SD).
  2. DMARDs, disease modifying anti-rheumatic drugs.
  3. *t-test, * p < 0.05.
  4. †chi-square test.
  5. ‡Non-biologic DMARDs included methotrexate, tacrolimus, salazosulfapyridine, leflunomide, D-penicillamine, bucillamine.
  6. §Biologics included etanercept, infliximab, golimumab, abatacept and tocilizumab.
Back to article page